NPC
TVRD

National Planning Corporation’s Tvardi Therapeutics TVRD Stock Holding History

National Planning Corporation’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-517
Closed -$306K – 771
2017
Q2 		$306K Sell
517
-865
-63% -$549K 0.02% 555
2017
Q1 		$867K Sell
1,382
-399
-22% -$213K 0.07% 261
2016
Q4 		$1.01M Buy
1,781
+75
+4% +$24.1K 0.08% 234
2016
Q3 		$515K Buy
1,706
+110
+7% +$23.8K 0.04% 358
2016
Q2 		$332K Buy
+1,596
New +$347K 0.03% 466

Other funds holding TVRD

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

National Planning Corporation's TVRD Position: Q3 2017 in Review

National Planning Corporation sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 517 shares — an estimated $306K sold.

National Planning Corporation first reported a position in TVRD in Q2 2016 and held it in 5 quarters. The position peaked at $1.01M in Q4 2016. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • National Planning Corporation reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • National Planning Corporation sold 517 Tvardi Therapeutics shares in Q3 2017, an estimated $306K.
  • National Planning Corporation first reported a position in Tvardi Therapeutics in Q2 2016 and held it in 5 quarters.
  • National Planning Corporation's Tvardi Therapeutics position peaked at $1.01M in Q4 2016.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on National Planning Corporation's 13F filing for Q3 2017, filed 13 Nov 2017.